600+ in-depth articles on Japanese heavy-ion therapy, immunotherapy, and precision medicine — stay current on international care and regenerative medicine.
The EU has approved Enhertu for previously treated HER2-positive metastatic solid tumours — the first tumour-agnostic HER2-directed antibody drug conjugate approval. Here's what it means for patients considering treatment options.
The FDA has approved ropeginterferon alfa-2b-njft (BESREMi Pen™) for polycythemia vera in the U.S. Here's what patients considering overseas treatment should know.
Lupin has received a US FDA tentative approval for a prostate cancer drug — what this regulatory step means, and what patients considering treatment in Japan should know.
The FDA has approved Aprepitant Injectable Emulsion by Azurity Pharmaceuticals. Here is what cancer patients considering treatment in Japan should know.
Ferring Pharma's Adstiladrin intravesical solution, a gene therapy for BCG-unresponsive bladder cancer, has received regulatory approval in Japan — here's what it means for patients considering treatment abroad.
Elevar Therapeutics CEO expects an FDA decision on a first-line liver cancer drug around July 23, 2026, with no outstanding review issues — what this may mean for patients exploring treatment options.
The FDA has approved new oncology drugs, imaging agents, and diagnostics. Here is what it means for patients considering treatment in Japan.
GSK's momelotinib has received Orphan Drug Designations in both the US and EU for VEXAS syndrome — a regulatory milestone, not yet a treatment approval. Here's what it means for patients.
The FDA has approved a Guardant Health companion diagnostic to help identify eligible patients for a new Boehringer Ingelheim cancer drug. Here's what it means for patients exploring treatment options.
Sawai Pharmaceutical announced expanded indications and dosage approval for Lenalidomide Capsules in Japan — here is what it may mean for patients considering treatment there.
One of Japan's top cancer hospitals has partnered with J&J to advance clinical trials — here's what it may mean for patients considering treatment in Japan.
Replimune has been given a third opportunity to seek US approval for a skin cancer drug. Here's what this regulatory development means for patients considering treatment in Japan.
RadioMedix has received U.S. FDA approval for a generic Ga-68 PSMA-11 imaging agent for prostate cancer. Here's what it means for patients considering care abroad.
Merck's Welireg and Keytruda combination has received regulatory approval for kidney cancer patients following surgery. Here's what it means if you're exploring treatment options.
The FDA has approved a new AbbVie drug for a rare blood cancer. Here's what international patients considering treatment in Japan should know before taking next steps.
Japan's pharmaceutical advisory committee has recommended approval for AstraZeneca's anticancer medicine Etocama and 10 other items — what this means for patients considering treatment in Japan.
The FDA has approved an ADC therapy developed by ImmunoGen (AbbVie) for a rare blood cancer. Here's what this means for patients considering treatment abroad, including in Japan.
The FDA has issued full approval for imatinib (Gleevec) in adjuvant GIST treatment. Here is what this U.S. decision may mean for patients considering care in Japan.
The FDA has approved an AbbVie antibody-drug conjugate (ADC) for an ultra-rare blood cancer. Here's what this means for patients considering treatment options in Japan.
AbbVie's DECNUPAZ has received FDA approval for blood cancer. Here's what this means for patients considering treatment options in Japan.
Replimune has resubmitted a cancer therapy for FDA approval after two prior rejections. Here's what patients considering treatment in Japan should know right now.
The FDA has granted accelerated approval to sonrotoclax (Begalzi) for relapsed or refractory mantle cell lymphoma. Here's what it means for patients exploring treatment options in Japan.
T-cell metabolic switching is key to generating sustained immune memory T-cells and is associated with anti-tumor responses, offering new hope for cancer immunotherapy.
The patented six-cell combination technology developed by founder Dr. Tsuneo Kuramochi (deceased) is now carried forward by Dr. Toshihide Aso at Dojin Clinic, providing new hope for advanced cancer patients.
Located in Shirokanedai, Tokyo, NEO Clinic Tokyo combines NGS and AI technology. Led by Dr. Lim Lay Ah Young and Dr. Yasuki Hijikata, the clinic creates personalized neoantigen vaccines tailored to your unique cancer profile.
IL-21-expressing NK cells demonstrate sustained anti-tumor activity against glioblastoma stem cell-like cells (GSCs). Both in vitro and in vivo experiments confirm this effect, bringing new breakthroughs in glioblastoma treatment.
[The New Integration of AI and Bladder Cancer Treatment] AI technology and machine learning are making bladder cancer treatment more personalized, helping doctors predict patient responses to chemotherapy. By utilizing whole-slide tumor imaging and gene expression analysis, th...
CAR-T cell therapy targeting neurodevelopmental pathways shows promise in suppressing the growth of glioblastoma multiforme (GBM), opening new avenues for brain tumor treatment.
Medical Supporter helps international patients access world-class medical treatment and guidance from Japan's top medical institutions.
Latest research suggests that PI3Kα pathway inhibitors, commonly used as cancer drugs, are also effective for patients with PTEN Hamartoma Tumor Syndrome (PHTS), helping to reduce vascular malformations and related pain, especially in younger patients.